Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01974752 · ClinicalTrials.gov registry record · Phase 3
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Phase 3 study of Uveal Melanoma and Metastatic, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT01974752: Completed Phase 3 study of Uveal Melanoma and Metastatic, sponsored by AstraZeneca.
NCT01974752 is a Phase 3 study of Uveal Melanoma and Metastatic that has completed, run by AstraZeneca. The registered enrollment target is 152 participants, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01974752, a Phase 3 study of Uveal Melanoma and Metastatic, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
Selumetinib therapy in patients with metastatic uveal melanoma.
Primary Outcome
Progression free survival (PFS) using blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Dacarbazine
- DRUG 75mg selumetinib
Study Locations (20)
Other
- Research Site - Edegem
- Research Site - Ghent
- Research Site - Kortrijk
- Research Site - Leuven
- Research Site - Olomouc
- Research Site - Prague
- Research Site - Hus
- Research Site - Nice
- Research Site - Paris
- Research Site - Heidelberg
- Research Site - München
California
- Research Site - Los Angeles
Colorado
- Research Site - Aurora
Georgia
- Research Site - Atlanta
Maryland
- Research Site - Lutherville
Missouri
- Research Site - St Louis
New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
What the finished NCT01974752 record still lists
NCT01974752 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target.
The record links to 2 conditions, with Uveal Melanoma appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT01974752 names 20 study sites across 10 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01974752 about?
NCT01974752 is a clinical study titled "Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)". Selumetinib therapy in patients with metastatic uveal melanoma.
What is the current status of trial NCT01974752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2014-04. Estimated completion is 2016-10.
What conditions does trial NCT01974752 study?
This clinical trial studies the following conditions: Uveal Melanoma, Metastatic.
What interventions are being tested in trial NCT01974752?
The interventions under investigation include: placebo (DRUG), Dacarbazine (DRUG), 75mg selumetinib (DRUG).
Who is sponsoring clinical trial NCT01974752?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01974752 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01974752's enrollment target sits among peer trials
152 8th of 29 higher than 22 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RECRUITING · Phase 3
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia